×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RHHBY – roche holding ltd s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RHHBY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
05:49 am
rhhby
Atlas of cells offers a milestone leap in understanding of the human body [CNN]
Low
Report
Atlas of cells offers a milestone leap in understanding of the human body [CNN]
11/19
02:15 pm
rhhby
Nykode Therapeutics And 2 More Penny Stocks Worth Watching [Yahoo! Finance]
Low
Report
Nykode Therapeutics And 2 More Penny Stocks Worth Watching [Yahoo! Finance]
11/19
07:34 am
rhhby
Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial [Yahoo! Finance]
Low
Report
Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial [Yahoo! Finance]
11/18
01:04 am
rhhby
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE [Yahoo! Finance]
Low
Report
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE [Yahoo! Finance]
11/14
09:32 am
rhhby
Flatiron Health announces research to be presented at American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
Low
Report
Flatiron Health announces research to be presented at American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
11/14
07:09 am
rhhby
Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024 [Yahoo! Finance]
Low
Report
Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024 [Yahoo! Finance]
11/12
04:24 pm
rhhby
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
07:00 am
rhhby
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Low
Report
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
UPDATE 1-European stock markets calm after pandemic-driven crash [Reuters]
13.0%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
TOP News Decliners
3/12
BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment [Reuters]
-9.0%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: